{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:43:55Z","timestamp":1792079035700,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["UGG10700"],"award-info":[{"award-number":["UGG10700"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004572","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["U114000"],"award-info":[{"award-number":["U114000"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.modpat.2026.101087","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:40:41Z","timestamp":1789688441000},"page":"101087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathologic and Molecular Insights Into ERBB2-Altered S100\/SOX10-Positive Uterine Sarcoma: A Report of 6 Cases"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5884-5819","authenticated-orcid":false,"given":"Zhuoyao","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-3176","authenticated-orcid":false,"given":"Huanwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2026.101087_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157645","article-title":"Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)","volume":"15","author":"P\u00e9rez-Fidalgo","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.modpat.2026.101087_bib2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/IGC.0b013e31825a97f6","article-title":"Sarcomas of uterine cervix: clinicopathological features, treatment, and outcome","volume":"22","author":"Khosla","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.modpat.2026.101087_bib3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PAS.0b013e318208f72e","article-title":"Endocervical fibroblastic malignant peripheral nerve sheath tumor (neurofibrosarcoma): report of a novel entity possibly related to endocervical CD34 fibrocytes","volume":"35","author":"Mills","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/PAS.0000000000001055","article-title":"NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma","volume":"42","author":"Chiang","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41379-018-0184-6","article-title":"Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms","volume":"32","author":"Croce","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2020.02.024","article-title":"Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss","volume":"157","author":"Lin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.modpat.2026.101087_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18654","article-title":"Molecular characteristics of gastric cancer with ERBB2 amplification","volume":"9","author":"Cao","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.modpat.2026.101087_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.2992089","article-title":"Amplification of a novel v-erbB-related gene in a human mammary carcinoma","volume":"229","author":"King","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.modpat.2026.101087_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.modpat.2026.101087_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102488","article-title":"The predictive role of ERBB2 point mutations in metastatic colorectal cancer: a systematic review","volume":"112","author":"Vaghi","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.modpat.2026.101087_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","article-title":"Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients","volume":"8","author":"Hong","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.modpat.2026.101087_bib12","first-page":"S941","article-title":"Recurrent activating ERBB2 V777L point mutation in fusion-negative, S100 and SOX10-positive uterine (corpus and cervix) spindle cell neoplasms","volume":"103","author":"Lin","year":"2023","journal-title":"Lab Invest"},{"key":"10.1016\/j.modpat.2026.101087_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00428-024-03908-3","article-title":"ERBB2\/ ERBB3-mutated S100\/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity","volume":"485","author":"Agaimy","year":"2024","journal-title":"Virchows Arch"},{"key":"10.1016\/j.modpat.2026.101087_bib14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00428-024-04003-3","article-title":"ERBB2\/ERBB3-mutated S100\/SOX10-positive uterine sarcoma: something new","volume":"486","author":"Shi","year":"2025","journal-title":"Virchows Arch"},{"key":"10.1016\/j.modpat.2026.101087_bib15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00428-025-04257-5","article-title":"ERBB2\/ERBB3-mutated S100\/SOX10-positive high-grade uterine sarcoma\u2014a case report on a rare entity","volume":"488","author":"Huang","year":"2026","journal-title":"Virchows Arch"},{"key":"10.1016\/j.modpat.2026.101087_bib16","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/modpathol.2017.97","article-title":"Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors","volume":"30","author":"Pekmezci","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2015.134","article-title":"Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics","volume":"29","author":"Schaefer","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.modpat.2026.101087_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.modpat.2026.101087_bib20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpobgyn.2011.07.003","article-title":"Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential","volume":"25","author":"Ip","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.modpat.2026.101087_bib21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/1097-0142(19840301)53:5<1143::AID-CNCR2820530521>3.0.CO;2-F","article-title":"Endometrioid stromal sarcomas of the ovary. A clinicopathologic analysis of 23 cases","volume":"53","author":"Young","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.modpat.2026.101087_bib22","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/cancers16183146","article-title":"Atypical spindle cell\/pleomorphic lipomatous tumor: a review and update","volume":"16","author":"Nishio","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2026.101087_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.semdp.2012.01.004","article-title":"Nonepithelial skin tumors with multinucleated giant cells","volume":"30","author":"G\u00f3mez-Mateo Mdel","year":"2013","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/modpathol.2017.69","article-title":"Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum","volume":"30","author":"Bennett","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/PAS.0000000000000677","article-title":"ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors","volume":"40","author":"Alassiri","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/gcc.22986","article-title":"Uterine inflammatory myofibroblastic tumor: first report of a ROS1 fusion","volume":"60","author":"Bennett","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.modpat.2026.101087_bib27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PAS.0000000000000404","article-title":"Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement","volume":"39","author":"Antonescu","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.modpat.2026.101087_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12905-025-03574-w","article-title":"NTRK rearranged spindle cell neoplasm of the uterine cervix: a rare case report and literature review","volume":"25","author":"Jiang","year":"2025","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.modpat.2026.101087_bib30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/PAS.0000000000001929","article-title":"NTRK-rearranged uterine sarcomas: clinicopathologic features of 15 cases, literature review, and risk stratification","volume":"46","author":"Costigan","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PGP.0000000000001143","article-title":"NTRK -rearranged spindle cell neoplasm of the uterus: an emerging entity","volume":"45","author":"Corbin","year":"2026","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/gcc.22910","article-title":"NTRK and other recently described kinase fusion positive uterine sarcomas: a review of a group of rare neoplasms","volume":"60","author":"Croce","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.modpat.2026.101087_bib33","article-title":"COL1A1::PDGFB fusion-associated uterine sarcoma and response to imatinib: a case report","volume":"49","author":"Chapagain","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.modpat.2026.101087_bib34","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/PAS.0000000000001644","article-title":"Neurofibrosarcoma revisited: an institutional case series of uterine sarcomas harboring kinase-related fusions with report of a novel FGFR1-TACC1 fusion","volume":"45","author":"Devereaux","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/PAS.0000000000001437","article-title":"Uterine cervical sarcoma with a novel RET-SPECC1L fusion in an adult: a case which expands the homology between RET-rearranged and NTRK-rearranged tumors","volume":"44","author":"Weisman","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/PAS.0000000000000909","article-title":"Inflammatory myofibroblastic tumors of the female genital tract are under-recognized: a low threshold for ALK immunohistochemistry is required","volume":"41","author":"Pickett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2026.101087_bib38","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2026.101087_bib39","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/2767-9764.CRC-24-0620","article-title":"Diverse ERBB2\/ERBB3 activating alterations and coalterations have implications for HER2\/3-targeted therapies across solid tumors","volume":"5","author":"Liu","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.modpat.2026.101087_bib40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/his.14292","article-title":"p53 immunohistochemical analysis of fusion-positive uterine sarcomas","volume":"78","author":"Mohammad","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2026.101087_bib41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41379-021-01005-3","article-title":"Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements","volume":"35","author":"Tsai","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/147323000903700332","article-title":"Comparison of the clinical and immunohistochemical features, including anaplastic lymphoma kinase (ALK) and p53, in inflammatory myofibroblastic tumours","volume":"37","author":"Jiang","year":"2009","journal-title":"J Int Med Res"},{"key":"10.1016\/j.modpat.2026.101087_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1\u2014a consensus overview","volume":"67","author":"Miettinen","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/a-2283-3714","article-title":"Malignant peripheral nerve sheath tumor (MPNST) of the uterine cervix\u2014a systematic literature review and new case report with possible new therapeutic approaches","volume":"85","author":"He","year":"2025","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.modpat.2026.101087_bib45","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/RLU.0000000000000299","article-title":"Enhanced CT and FDG PET\/CT in primary malignant peripheral nerve sheath tumor of the uterine cervix","volume":"39","author":"Dong","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.modpat.2026.101087_bib46","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/PAS.0000000000000655","article-title":"Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the French sarcoma group database","volume":"40","author":"Le Guellec","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib47","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/PAS.0000000000001242","article-title":"Recurrent SMARCB1 inactivation in epithelioid malignant peripheral nerve sheath tumors","volume":"43","author":"Schaefer","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib48","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.modpat.2026.101087_bib49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/neuonc\/noz028","article-title":"Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas","volume":"21","author":"Pemov","year":"2019","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.modpat.2026.101087_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1615749","article-title":"Diagnosis and treatment of 33 patients with primary melanoma of the female reproductive system","volume":"15","author":"Gao","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.modpat.2026.101087_bib51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1309\/3QR4FC5PPWXA7N29","article-title":"Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases","volume":"127","author":"Murali","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib52","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/00000478-200211000-00007","article-title":"Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases","volume":"26","author":"Gupta","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2026.101087_bib53","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/0008-5472.CAN-26-1313","article-title":"Genetic drivers of sensitivity or resistance to RAS(ON) multiselective inhibitors in NRAS-mutated melanoma","volume":"86","author":"Foth","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.modpat.2026.101087_bib54","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","article-title":"Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity","volume":"39","author":"Hanker","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.modpat.2026.101087_bib55","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.modpat.2026.101087_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e21553","article-title":"Characterization of ERBB2 alterations in non-small cell lung cancer","volume":"38","author":"Singh","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2026.101087_bib57","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e15155","article-title":"Real-world retrospective analysis of the mutation and co-mutation landscape of ERBB2 in advanced NSCLC","volume":"43","author":"Chiu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2026.101087_bib58","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-18-0430","article-title":"HER2 amplification in tumors activates PI3K\/Akt signaling independent of HER3","volume":"78","author":"Ruiz-Saenz","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.modpat.2026.101087_bib59","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1158\/1078-0432.CCR-17-0900","article-title":"Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.modpat.2026.101087_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.modpat.2026.101087_bib61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12032-016-0857-2","article-title":"Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient","volume":"34","author":"Hirotsu","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.modpat.2026.101087_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026760","article-title":"Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib","volume":"6","author":"Kancha","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.modpat.2026.101087_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2019.107526","article-title":"Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer","volume":"96","author":"Ding","year":"2020","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.modpat.2026.101087_bib64","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1172\/JCI130787","article-title":"Targetable ERBB2 mutations identified in neurofibroma\/schwannoma hybrid nerve sheath tumors","volume":"130","author":"Ronellenfitsch","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.modpat.2026.101087_bib65","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.modpat.2026.101087_bib66","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Cancer Netw"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:44:47Z","timestamp":1792075487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0893395226001304"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101087","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic and Molecular Insights Into ERBB2-Altered S100\/SOX10-Positive Uterine Sarcoma: A Report of 6 Cases","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101087"}}